Developer docs
API playgroundTry for free, no card

Search company profiles

AbCellera

Full company profile

uuid00004vn

Namestring
AbCellera
Legal namestring
AbCellera Biologics Inc.
Websiteurl
abcellera.com
Company typeenum
Public
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug discovery, therapeutic antibody development, bispecific antibody engineering, microfluidic single-cell screening, clinical antibody manufacturing
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Antibody Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and Collaboration Revenue
TypeLicensing Royalties
Description

AbCellera generates revenue through research collaborations with pharmaceutical and biotech partners, receiving upfront payments, research funding, milestone payments upon achievement of development milestones, and tiered royalties on net sales of approved products.

seekingalpha.com
2Internal Pipeline Development
TypeSubscription Recurring
Description

Company is transitioning from pure partnership model to developing proprietary drug candidates through clinical trials, with potential for future product revenue

seekingalpha.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AbCellera discovers and develops therapeutic antibody medicines using an integrated platform that combines proprietary microfluidic single-cell screening, AI-driven analysis, transgenic mouse technologies, and GMP clinical manufacturing. The company partners with pharmaceutical and biotechnology companies for antibody discovery programs (generating upfront, milestone, and royalty payments) while also advancing an internal proprietary pipeline of antibody candidates in women's health, immunology, autoimmunity, and oncology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100+ antibody drug programs completed with 16 candidates reaching clinical stage
+3 more records
Product overview1 text field

AbCellera is a clinical-stage biotechnology company that operates an integrated antibody discovery and development platform. The core offering is a technology platform that combines microfluidics, single-cell screening, AI, and transgenic mouse technologies to discover therapeutic antibodies. The company is advancing an internal pipeline of antibody programs including ABCL635 (NK3R for menopausal vasomotor symptoms in Phase 2), ABCL575 (OX40L for atopic dermatitis in Phase 1), ABCL688 (autoimmunity, IND-enabling), and ABCL386 (oncology). The platform capabilities include T-cell engager technology for bispecific antibody development and GPCR/ion channel technologies for complex membrane protein targets. AbCellera also operates a 130,000 sq ft GMP clinical manufacturing facility in Vancouver. The company partners with pharmaceutical companies including Lilly, AbbVie, Jazz, and others for discovery programs while building its proprietary pipeline.

Product and service6 records
1Antibody Discovery Platform
CategoryAntibody Discovery Platform
Description

Integrated antibody discovery service combining proprietary microfluidic single-cell screening, AI-driven analysis, and transgenic mouse technologies to discover and generate therapeutic antibody candidates from natural immune responses, contracted by pharmaceutical and biotech partners.

2ABCL635
CategoryInternal Pipeline Program - Endocrinology / Women's Health
Description

First-in-class antibody medicine targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause; first AbCellera-led program generated using GPCR and ion channel technologies, currently in Phase 1/2 clinical trials.

3ABCL575
CategoryInternal Pipeline Program - Immunology & Inflammation
Description

Investigative monoclonal antibody targeting OX40L with a modified Fc domain for treatment of moderate-to-severe atopic dermatitis, with potential applications to other inflammatory and autoimmune conditions; currently in Phase 1 clinical trial.

4ABCL688
CategoryInternal Pipeline Program - Autoimmunity
Description

Potential antibody medicine targeting a multipass complex membrane protein for treatment of an undisclosed indication in autoimmunity; second AbCellera-led program generated using GPCR and ion channel technologies, currently in IND-enabling studies.

5ABCL386
CategoryInternal Pipeline Program - Oncology
Description

Potential antibody medicine for treatment of an undisclosed indication in oncology, part of AbCellera's internal proprietary pipeline.

6T-Cell Engager Platform
CategoryAntibody Discovery Platform - T-Cell Engager Technology
Description

Platform for designing and engineering T-cell engaging bispecific antibodies to address challenging tumor types by incorporating novel CD3, co-stimulatory (CD28, 4-1BB), and multispecific modalities for oncology and immunology applications; partnered with Jazz Pharmaceuticals, AbbVie, and others.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

Preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies targeting gastrointestinal cancers and solid tumors. AbCellera receives $56M upfront for first two programs ($28M additional for third), with potential milestone payments up to $792M per program plus tiered royalties on net sales. Jazz receives exclusive worldwide development and commercialization rights.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Expanded partnership from 2020 collaboration (which produced COVID-19 antibodies bamlanivimab and bebtelovimab) to discover therapeutic antibodies in immunology, cardiovascular disease, and neuroscience. Lilly gains development and commercialization rights while AbCellera receives upfront, milestone, and royalty payments.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Expanded collaboration to develop novel T-cell engagers for oncology, building on existing partnership relationship.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner for antibody drug discovery programs across various therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner for antibody drug discovery programs across various therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner for antibody drug discovery programs across various therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner for antibody drug discovery programs across various therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner for antibody drug discovery programs across various therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner for antibody drug discovery programs across various therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner leveraging AbCellera's technology for target discovery and validation with best-in-class antibodies to advance genetically validated targets into potential antibody-based therapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Adimab operates a leading yeast-based antibody discovery platform serving pharma and biotech partners through licensing and collaboration agreements. Direct comparable to AbCellera in the antibody discovery platform-as-a-service model, though using different core technology (yeast display vs. microfluidics).

TypeDirect peer
Description

Absci is an AI-powered generative antibody discovery company combining high-throughput wet lab capabilities with deep learning models. Closely comparable to AbCellera in combining AI/ML-driven antibody design with proprietary wet-lab infrastructure for biologics discovery.

TypeDirect peer
Description

Genmab is a clinical and commercial-stage antibody therapeutics company with proprietary technology platforms (DuoBody, HexaBody, etc.) and a deep pipeline of partnered and proprietary antibody medicines. Comparable to AbCellera as a platform-driven antibody company generating revenue through partnerships and product royalties.

TypeDirect peer
Description

argenx is a commercial-stage immunology-focused antibody therapeutics company with its own proprietary antibody discovery platform (SIMPLE Antibody) and a portfolio of approved products including VYVGART. Comparable to AbCellera's transition toward proprietary clinical pipeline, with overlapping focus on immunology indications.

TypeDirect peer
Description

MacroGenics is a clinical-stage biopharmaceutical company focused on antibody-based therapeutics for cancer and autoimmune disease, with proprietary DART and TRIDENT platforms for bispecific antibodies. Directly comparable to AbCellera's T-cell engager platform and clinical-stage antibody pipeline.

TypeBroad incumbent
Description

Regeneron is a large established biopharmaceutical company with its own proprietary VelociSuite antibody discovery technologies and a deep pipeline of approved antibody medicines. Functions as both an AbCellera partner and a competitor demonstrating how incumbents build internal antibody capabilities.

TypeEmerging player
Description

Generate Biomedicines is an emerging AI-driven generative biology company focused on designing novel protein therapeutics including antibodies using foundation models. Represents a next-generation competitor to AbCellera's AI-enabled antibody discovery approach with backing from Flagship Pioneering.

TypeEmerging player
Description

Schrödinger operates a physics-based computational platform for drug discovery and materials science, including antibody and biologics design capabilities. Comparable to AbCellera's AI/ML-driven approach to therapeutic design, though broader in scope (small molecules plus biologics).

TypeBroad incumbent
Description

Eli Lilly is one of AbCellera's largest pharma partners (COVID-19 antibodies, immunology, cardiovascular, neuroscience collaborations). As a global pharma major with growing in-house biologics capabilities, Lilly represents both the most significant partnership counterparty and a potential long-term competitive threat in antibody discovery.

TypeEmerging player
Description

Recursion is an AI-driven drug discovery company combining high-throughput biology, automation, and machine learning to discover novel therapeutics. Comparable to AbCellera's data-driven approach to biologics discovery, though focused on small molecules and broader indication areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AbCellera

Biopharmaceutical Antibody Therapeuticsabcellera.com

AbCellera firmographics

Firmographics
Name
AbCellera
Legal name
AbCellera Biologics Inc.
Website
https://abcellera.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

AbCellera industry classification

Industry
Product category
Biopharmaceutical Antibody Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Antibody drug discovery
  • Therapeutic antibody development
  • Bispecific antibody engineering
  • Microfluidic single-cell screening
  • Clinical antibody manufacturing

Where AbCellera is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

AbCellera business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Partnership and Collaboration Revenue: AbCellera generates revenue through research collaborations with pharmaceutical and biotech partners, receiving upfront payments, research funding, milestone payments upon achievement of development milestones, and tiered royalties on net sales of approved products.
  2. Internal Pipeline Development: Company is transitioning from pure partnership model to developing proprietary drug candidates through clinical trials, with potential for future product revenue

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

AbCellera product offering

Product offering

Core offering

AbCellera discovers and develops therapeutic antibody medicines using an integrated platform that combines proprietary microfluidic single-cell screening, AI-driven analysis, transgenic mouse technologies, and GMP clinical manufacturing. The company partners with pharmaceutical and biotechnology companies for antibody discovery programs (generating upfront, milestone, and royalty payments) while also advancing an internal proprietary pipeline of antibody candidates in women's health, immunology, autoimmunity, and oncology.

Product overview

AbCellera is a clinical-stage biotechnology company that operates an integrated antibody discovery and development platform. The core offering is a technology platform that combines microfluidics, single-cell screening, AI, and transgenic mouse technologies to discover therapeutic antibodies. The company is advancing an internal pipeline of antibody programs including ABCL635 (NK3R for menopausal vasomotor symptoms in Phase 2), ABCL575 (OX40L for atopic dermatitis in Phase 1), ABCL688 (autoimmunity, IND-enabling), and ABCL386 (oncology). The platform capabilities include T-cell engager technology for bispecific antibody development and GPCR/ion channel technologies for complex membrane protein targets. AbCellera also operates a 130,000 sq ft GMP clinical manufacturing facility in Vancouver. The company partners with pharmaceutical companies including Lilly, AbbVie, Jazz, and others for discovery programs while building its proprietary pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antibody Discovery Platform Integrated antibody discovery service combining proprietary microfluidic single-cell screening, AI-driven analysis, and transgenic mouse technologies to discover and generate therapeutic antibody candidates from natural immune responses, contracted by pharmaceutical and biotech partners.
  • ABCL635 First-in-class antibody medicine targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause; first AbCellera-led program generated using GPCR and ion channel technologies, currently in Phase 1/2 clinical trials.
  • ABCL575 Investigative monoclonal antibody targeting OX40L with a modified Fc domain for treatment of moderate-to-severe atopic dermatitis, with potential applications to other inflammatory and autoimmune conditions; currently in Phase 1 clinical trial.
  • ABCL688 Potential antibody medicine targeting a multipass complex membrane protein for treatment of an undisclosed indication in autoimmunity; second AbCellera-led program generated using GPCR and ion channel technologies, currently in IND-enabling studies.
  • ABCL386 Potential antibody medicine for treatment of an undisclosed indication in oncology, part of AbCellera's internal proprietary pipeline.
  • T-Cell Engager Platform Platform for designing and engineering T-cell engaging bispecific antibodies to address challenging tumor types by incorporating novel CD3, co-stimulatory (CD28, 4-1BB), and multispecific modalities for oncology and immunology applications; partnered with Jazz Pharmaceuticals, AbbVie, and others.

Quantifiable outcome

  • 100+ antibody drug programs completed with 16 candidates reaching clinical stage
  • +3 more outcomes

Companies that use AbCellera

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles1 record

AbCellera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

AbCellera partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered major and core.

  • Jazz PharmaceuticalsmajorStrategic or Co-development Partner · 17 June 2026Preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies targeting gastrointestinal cancers and solid tumors. AbCellera receives $56M upfront for first two programs ($28M additional for third), with potential milestone payments up to $792M per program plus tiered royalties on net sales. Jazz receives exclusive worldwide development and commercialization rights.
  • Eli LillycoreStrategic or Co-development PartnerExpanded partnership from 2020 collaboration (which produced COVID-19 antibodies bamlanivimab and bebtelovimab) to discover therapeutic antibodies in immunology, cardiovascular disease, and neuroscience. Lilly gains development and commercialization rights while AbCellera receives upfront, milestone, and royalty payments.
  • AbbViecoreStrategic or Co-development PartnerExpanded collaboration to develop novel T-cell engagers for oncology, building on existing partnership relationship.
  • RegeneroncoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
  • NovartiscoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
  • IncytecoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
  • BiogencoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
  • GileadcoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
  • Prelude TherapeuticscoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
  • EmpiricocoreStrategic or Co-development PartnerPartner leveraging AbCellera's technology for target discovery and validation with best-in-class antibodies to advance genetically validated targets into potential antibody-based therapies.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

AbCellera competitors and assessment

Company assessment

Direct peers

  • Adimab: Adimab operates a leading yeast-based antibody discovery platform serving pharma and biotech partners through licensing and collaboration agreements. Direct comparable to AbCellera in the antibody discovery platform-as-a-service model, though using different core technology (yeast display vs. microfluidics).
  • Absci: Absci is an AI-powered generative antibody discovery company combining high-throughput wet lab capabilities with deep learning models. Closely comparable to AbCellera in combining AI/ML-driven antibody design with proprietary wet-lab infrastructure for biologics discovery.
  • Genmab: Genmab is a clinical and commercial-stage antibody therapeutics company with proprietary technology platforms (DuoBody, HexaBody, etc.) and a deep pipeline of partnered and proprietary antibody medicines. Comparable to AbCellera as a platform-driven antibody company generating revenue through partnerships and product royalties.
  • argenx: argenx is a commercial-stage immunology-focused antibody therapeutics company with its own proprietary antibody discovery platform (SIMPLE Antibody) and a portfolio of approved products including VYVGART. Comparable to AbCellera's transition toward proprietary clinical pipeline, with overlapping focus on immunology indications.
  • MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company focused on antibody-based therapeutics for cancer and autoimmune disease, with proprietary DART and TRIDENT platforms for bispecific antibodies. Directly comparable to AbCellera's T-cell engager platform and clinical-stage antibody pipeline.

Broad incumbents

  • Regeneron Pharmaceuticals: Regeneron is a large established biopharmaceutical company with its own proprietary VelociSuite antibody discovery technologies and a deep pipeline of approved antibody medicines. Functions as both an AbCellera partner and a competitor demonstrating how incumbents build internal antibody capabilities.
  • Eli Lilly: Eli Lilly is one of AbCellera's largest pharma partners (COVID-19 antibodies, immunology, cardiovascular, neuroscience collaborations). As a global pharma major with growing in-house biologics capabilities, Lilly represents both the most significant partnership counterparty and a potential long-term competitive threat in antibody discovery.

Emerging players

  • Generate Biomedicines: Generate Biomedicines is an emerging AI-driven generative biology company focused on designing novel protein therapeutics including antibodies using foundation models. Represents a next-generation competitor to AbCellera's AI-enabled antibody discovery approach with backing from Flagship Pioneering.
  • Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and materials science, including antibody and biologics design capabilities. Comparable to AbCellera's AI/ML-driven approach to therapeutic design, though broader in scope (small molecules plus biologics).
  • Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company combining high-throughput biology, automation, and machine learning to discover novel therapeutics. Comparable to AbCellera's data-driven approach to biologics discovery, though focused on small molecules and broader indication areas.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AbCellera social profiles

Digital presence

AbCellera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AbCellera leadership team

Management profile

Number of profiles

Profiles10 records

AbCellera funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AbCellera M&A and investment

M&A and investment

M&A4 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AbCellera

What does AbCellera do?

AbCellera discovers and develops therapeutic antibody medicines using an integrated platform that combines proprietary microfluidic single-cell screening, AI-driven analysis, transgenic mouse technologies, and GMP clinical manufacturing. The company partners with pharmaceutical and biotechnology companies for antibody discovery programs (generating upfront, milestone, and royalty payments) while also advancing an internal proprietary pipeline of antibody candidates in women's health, immunology, autoimmunity, and oncology.

Is AbCellera a public or private company?

AbCellera is a public company. It is classified as public and is currently operating.

When was AbCellera founded?

AbCellera was founded in 2012. It employs 501 to 1,000 people.

Where is AbCellera based?

AbCellera is headquartered in Vancouver, Canada, in the North America region.

How does AbCellera make money?

Two revenue lines are on record. Partnership and Collaboration Revenue is the primary driver. The others are internal Pipeline Development.

Who are AbCellera's main competitors?

Direct peers on record are Adimab, Absci, Genmab, argenx and MacroGenics. Broad incumbents are Regeneron Pharmaceuticals and Eli Lilly. Emerging players are Generate Biomedicines, Schrödinger and Recursion Pharmaceuticals.

Does AbCellera have an API?

No public API is recorded for AbCellera.

What industry is AbCellera in?

AbCellera's product category is Biopharmaceutical Antibody Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaAbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 TranscriptAbCellera Biologics CEO Carl Hansen presented at the UBS Global Biopharma Conference, outlining the company's 14-year history and its antibody discovery platform. He highlighted success with COVID-19 therapeutics and recent traction in T-cell engagers, while noting the company's focus on GPCRs, ion channels, and T-cell engagers.Seeking AlphaSoftBank exits Satellogic, trims stakes in Nu Holdings, VTEX, Ethos, AbCellera in Q3SoftBank Group Corp. liquidated its position in Satellogic and reduced holdings in Nu Holdings, VTEX, Ethos Technologies, and AbCellera during Q3. The company also exited its stake in Satellogic, a satellite communications firm.TradingViewAbCellera Biologics Inc. Stock 12‑Month Price Target Raised to $18.55, Implies 61% UpsideAnalysts' average price target for AbCellera Biologics was raised to $18.55 from $18, implying about 61% upside from the Nov. 13 closing price. The consensus remains a Buy across 13 analysts, with 12 Buys, 1 Hold, and 0 Sells.Seeking AlphaAbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptAbCellera CEO Carl Hansen presented at Stifel's 2026 Healthcare Conference, highlighting ABCL635 as the first evidence of the company's platform. He discussed Phase II data from August, comparing efficacy and safety to standard-of-care oral small molecules.TradingViewAbCellera 10% Owner Purchased Shares Worth Over $698KThermopylae Holdings Ltd., a 10% owner of AbCellera Biologics, purchased 60,565 common shares at a weighted-average price of $11.54 per share, totaling $698,920. The transaction increased its direct ownership to 56,194,662 shares.American Banking and Market NewsAbCellera Biologics (NASDAQ:ABCL) Stock Gets Price Target Boost from Stifel NicolausStifel Nicolaus raised its price target on AbCellera Biologics from $9.00 to $14.00, keeping a buy rating. The stock opened at $11.95, with a consensus price target of $16.33. The company reported Q3 EPS of -$0.13, beating estimates of -$0.17.Simply Wall StDid Phase 2 Trial Success Just Shift AbCellera's (ABCL) Investment Narrative?AbCellera Biologics reported Q3 2026 revenue of $10.64 million and a loss per share of $0.13, below analyst forecasts. The company also announced positive Phase 2 results for ABCL635 in vasomotor symptoms and plans to move the drug into late-stage development in 2027. The firm raised $200 million in equity, signaling a shift toward internally owned assets.FierceBiotechAbCellera becomes latest biotech to abandon dream of developing OX40 drugAbCellera abandoned its OX40 antibody ABCL575 after a phase 1 study showed favorable tolerability and pharmacokinetics, citing external developments in the OX40 class. The decision follows Kyowa Kirin's shutdown of rocatinlimab studies and Sanofi's cancellation of amlitelimab. AbCellera will focus on ABCL635, a neurokinin 3 receptor antibody.American Banking and Market NewsAnalyzing AbCellera Biologics (NASDAQ:ABCL) & Anika Therapeutics (NASDAQ:ANIK)Anika Therapeutics and AbCellera Biologics are compared on profitability, valuation, and analyst ratings. Anika beats AbCellera on 9 of 15 factors, with higher revenue, lower P/E, and a 51% upside versus 26% for AbCellera. Analysts favor Anika's lower volatility and stronger institutional ownership.MarketBeatWhat AbCellera Biologics (ABCL) Said on Its Q3 Earnings CallAbCellera Biologics reported positive mid-stage results for its hot flash treatment ABCL635, with an 83% reduction in moderate or severe hot flashes versus 33% for placebo. The company plans to advance ABCL635 to late-stage development in 2027 and reported a net loss of $41 million with over $890 million in available liquidity.